Drugs / GW003
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02725606 | Mar 2016 → Sep 2017 | neutropenia | Jiangsu T-Mab Biopharma Co.,Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT02643901 | Sep 2015 → Oct 2016 | neutropenia | Jiangsu T-Mab Biopharma Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02156388 | Aug 2013 → Feb 2015 | metastatic neoplasm, neutropenia | Jiangsu T-Mab Biopharma Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02725606 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant(Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I)Fusion Protein” NCT02156388 ↗ |
| Route | Subcutaneous | “single subcutaneous(SC) injection of GW003” NCT02156388 ↗ |